Navigation Links
Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
Date:11/2/2007

HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.

The FDA had previously reviewed Phase I through III clinical data involving gepirone ER. In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval as a new antidepressant treatment. Subsequently, FKP successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.

Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.

Fabre-Kramer and GlaxoSmithKline entered an agreement in February of this year for collaboration on the worldwide development and commercialization of gepirone extended-release tablets. Fabre-Kramer and GSK are evaluating the response from the FDA to determine appropriate next steps.

About Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals, headquartered in Houston, Texas, is engaged in acquiring, developing and commercializing psychotropic drugs that have significant market potential. In addition to gepirone ER, Fabre-Kramer has 10 other compounds in various stages of development for indications including depression, anxiety, schizophrenia, Parkinson's disease and insomnia. For more information,
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... ATLANTA , Nov. 18, 2014   Rio ... partnership with University of Texas Health Science Center ... Brownsville , has selected Wellcentive,s suite ... empower providers in a four-county area to partner with ... the health of their Medicaid and uninsured patient populations, ...
(Date:11/18/2014)... Calif. , Nov. 17, 2014   ... Products Inc. (OTC: GWPC) is a diversified company. ... and convenience of advanced technology and proven expertise ... fundamental business of health and wellness.  WholeHEALTH Products, ... hospitals, doctors, clinics and healthcare centers, and 8 ...
(Date:11/18/2014)... N.J. , Nov. 18, 2014  A new ... countries finds that a large majority of the general ... cancer (84%), a devastating disease that is responsible for ... prostate cancers combined 1,2,4 . The "Any One Any ... understanding about the widespread impact of lung cancer, but ...
Breaking Medicine Technology:Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 2Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 3Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 4WholeHEALTH Product Inc. to File FDA Emergency Use Approval (EUA) for PCR Rapid Ebola Test 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 3Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 4Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 5Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 6
... Pharmaceuticals announced today that it has filed its first ... Drug Administration (FDA).  The recently filed product has been ... seven years of market exclusivity. In addition, the FDA ... primarily due to the safety advantages it offers. Fast ...
... that a new market research report is available in its ... Latin America http://www.reportlinker.com/p0192647/The-Outlook-for-Medical-Devices-in-Latin-America.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Brazil Chile Colombia ... Peru Venezuela The ...
Cached Medicine Technology:Arbor Pharmaceuticals Announces Filing of First NDA 2The Outlook for Medical Devices in Latin America 2The Outlook for Medical Devices in Latin America 3The Outlook for Medical Devices in Latin America 4
(Date:11/18/2014)... CA (PRWEB) November 18, 2014 As ... new routines, many people look at fall as the ... Dr. Kevin Sadati , Orange County facial plastic ... Newport Beach practice. At the Gallery of Cosmetic ... taking advantage of his non-invasive cosmetic surgery procedures. ...
(Date:11/18/2014)... Haelle HealthDay Reporter MONDAY, ... experience a severe abusive head trauma before the age of ... new study. In addition, among those who survive ... the study found. Abusive head trauma includes shaken baby ... suffers head injuries, according to background information in the study. ...
(Date:11/18/2014)... Dennis Thompson ... News) -- Daily low-dose aspirin therapy may not have ... The study, which involved more than 14,000 ... difference in heart-related deaths or non-fatal heart attacks and ... didn,t. "It indicates that primary prevention with ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. ... can safely take aspirin combined with a blood-thinning medication, new ... patient,s risk of early death, according to a new study ... Association in Chicago. The report was also published online Nov. ... from more than a dozen clinical trials revealed no increase ...
(Date:11/18/2014)... 17, 2014 (HealthDay News) -- Until recently, insect-transmitted Chagas disease ... it has made its way to the United States over ... is typically transmitted via the bite of the "kissing bug," ... now a new study suggests that common bedbugs might be ... acquire and transmit the parasite. Our next step is to ...
Breaking Medicine News(10 mins):Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 3
... , , , DURHAM, ... announced that company chairman and CEO, Chris Stern, will present at an ... The presentation will be at the Zurich Airport Radisson Hotel and ... webcast but will be open to interested investors. , ...
... WESTFORD, Mass., Sept. 22 Cynosure, Inc. (Nasdaq: ... array of light-based aesthetic treatment systems, today announced that President and ... will present at the third annual Maxim Group Growth Conference in ... will be webcast live over the Internet beginning at 10:00 a.m. ...
... may have boosted seniors, sexually transmitted infection rates, researchers ... widowers who recently lost their wives are more likely ... who are still married, a new study has found. ... drugs like Viagra could boost the risk, noting the ...
... , , SEATTLE, Sept. 22 ... firms, announced today that it has opened a new office in ... offices, will continue to serve existing clients while expanding the range ... "Milliman,s wide range of talents and sixty-plus years of experience ...
... , , MOUNTAIN ... in devices for clot removal in ischemic stroke patients, today announced ... DAC catheters are a first-in-class family of devices used to provide ... and other neurovascular procedures. , , The ...
... , PITTSBURGH, Sept. 22 Cohera Medical, ... the ISO 13485:2003 International Standard for the Design, Development, ... certification allows Cohera Medical to proceed with the CE ... novel internal surgical adhesive, upon completion of development for ...
Cached Medicine News:Health News:Cynosure to Present at the Maxim Group Growth Conference 2Health News:Sex With New Partners Raises Widowers' Disease Risk 2Health News:Milliman Announces the Opening of a New Office in San Juan, Puerto Rico 2Health News:Concentric Medical Launches Full Family of DAC(TM) Neurovascular Catheters 2Health News:Cohera Medical Receives ISO 13485 Certification: Company Meets International Standards for Design, Development and Manufacturing of Medical Devices 2
... D.O.R.C. Intraocular Electromagnet offers a truly unique ... intraocular foreign bodies (IOFB). Other magnets are ... offers an intraocular electromagnet for use through ... surgical technique. The D.O.R.C. Intraocular Electromagnet offers ...
... The new SureSigns VS1 ... vital signs monitor that provides ... seconds. The VS1 is designed ... with features like large, bright, ...
... continuous monitoring, the M3 and M4 monitors ... neonatal patient care. M Series monitors are ... a basic set of non-invasive parameters and ... Multi-Measurement Server extensions offer Mainstream or Microstream® ...
Compact networked patient monitors for flexible care....
Medicine Products: